The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia
Not Applicable
- Conditions
- Advanced non-small cell lung cancer with idiopathic interstitial pneumonia
- Registration Number
- JPRN-UMIN000021591
- Lead Sponsor
- Hirosaki University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Uncotrollable angiona pectorias, cardian infarction, haear failure, diabetes mellitus, hypertension 2) Using prednisolone >10mg/day 3) Active infection 4) Active double cancers 5) symptomatic brain metastasis 6) Patients with uncontrolled pleural or pericardial effusion, or ascites 7) pregnancy 8) Patient with a history of allergy to CBDCA, PTX and nintedanib 9) Inappropriate patients in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of treatment-related ILD
- Secondary Outcome Measures
Name Time Method RR: response rate OS: overall survival PFS: progression free survival